Pharmazz Inc. announces FDA clearance of an IND application for a Phase II clinical trial of centhaquine (PMZ-2010) in COVID-19 patients with ARDS
10 mars 2022 08h00 HE
|
Pharmazz, Inc.
WILLOWBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Pharmazz (“Pharmazz”), Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in...
Pharmazz Inc. Announces Completion of Enrollment of Phase III Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke
17 févr. 2022 08h00 HE
|
Pharmazz, Inc.
WILLOWBROOK, Ill., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in...
Pharmazz Inc. submits Investigational New Drug Application to India Central Drugs Standard Control Organization for a Phase II clinical trial of sovateltide (PMZ-1620) in hypoxic-ischemic encephalopathy in neonates
03 févr. 2022 08h00 HE
|
Pharmazz, Inc.
Sovateltide is an endothelin-B receptor agonist that has been shown to increase blood flow, show anti-apoptotic activity, and produce neurovascular remodeling Sovateltide is also in Phase III...